BOULDER, Colo.--(BUSINESS WIRE)--Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix® with up to $20 million of capital.
Help employers find you! Check out all the jobs and post your resume.
